DIRS.INFO The most relevant business & tech news

☆ Sales, spins and splits — what are the differences and why do they matter for investors like us?
▼ + stars: | 2023-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +20 min

Investors may get one share in the spun-out entity for every share of the parent company they owned. What's left of J & J will be focused on pharmaceuticals and medical technologies, which were responsible for over 84% of the company's total 2022 revenue of $94.94 billion. It underscores that once free of the parent company tethers a divested company can chart its own destiny. Those priorities may not have necessarily been wrong when considering J & J as the overall enterprise. We believe J & J and Danaher are poised to deliver two more examples.

☆ Watch CNBC's full interview with Eli Lilly CEO David Ricks
▼ + stars: | 2023-04-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Eli Lilly CEO David RicksEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the drugmaker's Q1 earnings results, which missed on earnings but beat on revenue, and the company outlook for the rest of the year.

☆ Eli Lilly CEO David Ricks on Q1 earnings: This will be a year of both growth and investment
▼ + stars: | 2023-04-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO David Ricks on Q1 earnings: This will be a year of both growth and investmentEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the drugmaker's Q1 earnings results, which missed on earnings but beat on revenue, and the company outlook for the rest of the year.

Patients who took Eli Lilly 's weight loss drug tirzepatide lost up to 34 pounds on average, or 16% of their body weight, the company said in clinical trial results released Thursday. Eli Lilly plans to complete its application for Food and Drug Administration approval of the drug in the coming weeks and expects regulatory action as early as later this year. The FDA approved tirzepatide for Type 2 diabetes last year, but the drug is not cleared for weight loss. The approval would open "up the opportunity for many more people to benefit from tirzepatide," Eli Lilly CEO David Ricks said Thursday on CNBC's "Squawk Box." He added that the drug sets a "new bar for weight loss and people with diabetes."

☆ Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices
▼ + stars: | 2023-04-21 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

In this photo illustration, an insulin pen manufactured by the Novo Nordisk company is displayed on March 14, 2023 in Miami, Florida. Those companies — Eli Lilly, Novo Nordisk and Sanofi — had announced in March that they will slash prices of their most widely used insulin products by 70% or more. The companies' versions of insulin cost at least $275 before the announced price slashes, Sanders noted. Novo Nordisk said its CEO looks forward to "a productive and collaborative discussion about this important issue." PBMs have come under criticism for inflating drug prices and not passing on all the discounts they negotiate to consumers.

☆ Biden budget would cap monthly insulin prices at $35 for people with private insurance
▼ + stars: | 2023-03-09 | by ( Spencer Kimball | ) www.cnbc.com time to read: +1 min

President Joe Biden's federal budget proposal would cap insulin prices at $35 per month for people with private insurance plans. Biden called on Congress in his State of the Union speech to finish the job and cap insulin at $35 a month for everybody. Drugmaker Eli Lilly got ahead of a potential federal mandate, announcing earlier this month that it would cap insulin at $35 per month for people with private insurance at certain retail pharmacies. About 40% of people with diabetes have private insurance while 5% are not insured, according to the American Diabetes Association. Some Republicans in Congress oppose to the move to cap insulin prices.

☆ Inside the fierce debate over clean hydrogen, with $100 billion in federal subsidies on the line
▼ + stars: | 2023-03-03 | by ( Catherine Clifford | In Catclifford | ) www.cnbc.com time to read: +13 min

The impact of the tax credit on emissions reductions depends on how federal agencies implement it. On one side of the debate, some energy providers say that making the rules too strict could kill the clean hydrogen industry before it ever gets off the ground. CERAWeek returned in-person to Houston celebrating its 40th anniversary with the theme "Pace of Change: Energy, Climate, and Innovation." This hourly approach to energy accounting has been adopted by Google, which has been a forerunner in adopting clean energy, for example. In the long run, Garabedian says, his stance is about protecting his company, the industry's reputation, and the tax credit.

Eli Lilly, along with Sanofi (SASY.PA) and Novo Nordisk (NOVOb.CO) make up 90% of the U.S. market for insulin. Biden, a Democrat, on Tuesday called on Congress and other manufacturers to lower the price of insulin as Lilly had done. The list price for Lispro, a cheaper version of its Humalog insulin, is currently $82.41 for 100 units/mL vials. List prices for drugs often differ from what patients actually pay, including after insurance and other assistance programs. Ricks said the company's insulin price cuts had been planned for some time and were accounted for in Eli Lilly's December financial forecast, which projected 2023 revenue of at least $30.3 billion.

☆ Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugs
▼ + stars: | 2023-03-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugsCNBC's Meg Tirrell and David Ricks, Eli Lilly CEO, joins 'Closing Bell: Overtime' to discuss the company's decision to slash insulin prices. He also discusses his economic outlook and the timeline for approval of drugs in its pipeline.

☆ Lilly to cut U.S. insulin prices by 70% from fourth quarter
▼ + stars: | 2023-03-01 | by ( ) www.reuters.com time to read: +2 min

March 1 (Reuters) - Eli Lilly and Co (LLY.N) will cut list prices by 70% for its most commonly prescribed forms of insulin, Humalog and Humulin, beginning from the fourth quarter of this year, the drugmaker said on Wednesday. Around 8.4 million of the 37 million people in the United States with diabetes use insulin, according to the American Diabetes Association. Eli Lilly, along with Sanofi (SASY.PA) and Novo Nordisk (NOVOb.CO) make up 90% of the U.S. market for insulin. Drugmakers had previously priced insulin at more than $275 a vial, representing a 1,200% increase in price over the past 20 years, according to the advocacy group Insulin Initiative. Reporting by Bhanvi Satija in Bengaluru; Additional reporting by Susan Heavey, Editing by Arun KoyyurOur Standards: The Thomson Reuters Trust Principles.

☆ Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance
▼ + stars: | 2023-03-01 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

The Inflation Reduction Act capped insulin prices for Medicare beneficiaries at $35 per month but did not protect people with private insurance or who don't have coverage from higher prices. In President Joe Biden's State of the Union speech, he called on Congress to cap insulin prices at $35 a month for everyone. Lilly said it will cap out-of-pocket costs at $35 per month effectively immediately at certain retail pharmacies for people with private insurance. One in five people with diabetes who have private insurance pay more than $35 per month for insulin, according to the Kaiser Family Foundation. Democrats in Congress had pushed to cap insulin at $35 per month last summer for people with private insurance, but Senate Republicans killed the measure.

☆ These are Wall Street's favorite defensive stocks as the market's early momentum this year wanes
▼ + stars: | 2023-02-21 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

However, defensive stocks are likely to better withstand a market downturn given their strong balance sheet and consistent revenue stream. With that in mind, CNBC Pro looked for Wall Street's favorite defense stocks. At least 60% of the analysts covering the stock rate it a buy, per FactSet. Visa and Mastercard have more than 70% of the analysts covering the stocks rating them a buy. The stock has 17% upside to the average analyst price target and 68% of analysts covering it rate the name a buy.

"When you think about traditional drug and vaccine development and longevity of sales, it's usually much more spread out," Morningstar analyst Damien Conover said. The sudden inflow of revenue should prod companies to strike deals and link up with new partners, he said. Vaccine maker Moderna also expects 2023 revenue to fall sharply. The company's only product - its messenger RNA COVID vaccine - pulled in around $18.4 billion in 2022. Eli Lilly and Co (LLY.N) made $2 billion in 2022 from monoclonal antibody COVID treatments and is not expecting any revenue from the business in 2023.

☆ Eli Lilly CEO weighs in on Q4 revenue miss
▼ + stars: | 2023-02-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO weighs in on Q4 revenue missEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's change in guidance, the outlook for the company's Diabetes drug, and Eli Lilly's manufacturing capacity of the new drug, Mounjaro.

☆ Eli Lilly's post-earnings decline is creating a buying opportunity for long-term investors
▼ + stars: | 2023-02-02 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly (LLY) reported mixed fourth-quarter results Thursday morning, but we're looking through the stock's post-earnings sell-off because there's no change to the pharmaceutical giant's bright long-term potential. Bottom line There's definitely some noise surrounding Eli Lilly's results, including sales of its key diabetes drug Mounjaro. Eli Lilly began its rolling submission to the FDA in late 2022. None of them undercut the multiyear Eli Lilly investment story, making Thursday's stock sell-off an attractive buying opportunity. It is a "very complicated" process to make that kind of drug, Ricks said, so it cannot just scale up overnight.

☆ Eli Lilly investors spooked by weak Mounjaro sales, but it's the obesity drug approval that will unlock its value
▼ + stars: | 2023-02-02 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Lilly said slightly more than 50% of commercial and Part D subscribers have access to the drug via their insurance plans. But new classes of weight loss medications are helping to change this mindset. Still, legislation will be necessary to get coverage of Mounjaro for obesity and overweight treatment by Medicare plans. By law, these plans are banned from paying for weight loss medications. Wegovy and Mounjaro One encouraging sign: Lilly competitor Novo Nordisk has gained access to more than 80% of insurance company formularies for their obesity treatment, Wegovy.

☆ Eli Lilly's Alzheimer's drug hits a regulatory hurdle. But our belief in the stock isn't shaken
▼ + stars: | 2023-01-20 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's (LLY) attempt to receive accelerated regulatory approval for its Alzheimer's drug donanemab has been rejected. Eli Lilly said it will keep working with the FDA to "evaluate the fastest pathway" for donanemab to reach patients. Indeed, analysts at Barclays wrote in a note to clients Thursday that "we now see [accelerated approval] off the table." LLY 1Y mountain Eli Lilly (LLY) 1-year performance "It's definitely not a thesis-breaker," Bank of America analyst Geoff Meacham told CNBC on Friday. David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC

☆ Drug companies favor biotech meds over pills, citing new U.S. law
▼ + stars: | 2023-01-13 | by ( Deena Beasley | ) www.reuters.com time to read: +5 min

The pharmaceutical industry, whose members gathered in the thousands this week in San Francisco for the annual JP Morgan Healthcare conference, opposed the legislation and has begun implementing strategies to mitigate its impact. "In 10 years, we'll have far fewer small molecules being developed than we do today." He questioned the benefit of "rules that really just disincentivize investment in what ends up being convenient drugs, drugs for tough conditions like cancer and drugs that get really cheap when they go generic." Most medicines on the market today are small molecules, which can be taken by mouth, absorbed into the bloodstream and easily penetrate cell membranes. He noted it is not unusual for pharmaceutical companies to choose not to pursue a drug they once thought promising.

☆ Eli Lilly has spent years and billions of dollars in search of an effective Alzheimer's drug. But success is not all or nothing for the stock
▼ + stars: | 2023-01-09 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +22 min

Eli Lilly (LLY) has spent decades researching Alzheimer's disease without successfully bringing to market a treatment that slows the memory-destroying condition. For Eli Lilly as a company, an Alzheimer's drug is an important pursuit. Lilly's Alzheimer's history Eli Lilly's "first real foray" into Alzheimer's came in the 1990s, according to Dr. John Sims, Eli Lilly's head of medical development for donanemab. Financial implications for Lilly LLY mountain 2021-10-08 The Club started a new position in Eli Lilly (LLY) in October 2021. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

If the Fed doesn't have to tighten as hard, many stocks are at levels you want to buy." Rival Alzheimer's drug approval good for Lilly, too JM: "Biogen is getting accelerated approval for that new Alzheimer's drug. [ Eli Lilly CEO] David Ricks says ... confidence in the Alzheimer's class is going to be good for them as well. Can't be greedy: We need to sell some EL JM: " Estee Lauder , what should we do about it?" As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ What increasing confidence in Biogen's latest Alzheimer's drug means for Eli Lilly
▼ + stars: | 2022-11-30 | by ( ) www.cnbc.com time to read: +6 min

Donanemab is the name of Eli Lilly's Alzheimer's drug in its own late-stage trials. JPMorgan has a neutral (hold) rating on Biogen shares and an overweight (buy) rating on Eli Lilly shares. What it means for Eli Lilly Eli Lilly has a phase three trial underway for its donanemab Alzheimer's drug that is similar to lecanemab, which is why the Biogen-Eisai data has been interpreted as favorable for the Club holding. Clumps of the protein, known as amyloid plaques, are one of the key markers of Alzheimer's disease. Previous drugs developed around the a-beta hypothesis — including those from Eli Lilly — have failed to meaningfully delay the disease's progression.

☆ Fake account shows 'challenges' with Twitter - Lilly CEO
▼ + stars: | 2022-11-16 | by ( ) www.reuters.com time to read: +1 min

[1/3] FILE PHOTO: Twitter app logo is seen in this illustration taken, August 22, 2022. REUTERS/Dado Ruvic/Illustration/File Photo/File PhotoNov 16 (Reuters) - Eli Lilly & Co (LLY.N) Chief Executive Officer Dave Ricks said on Wednesday that the recent imposter Twitter account incident "demonstrates some of the challenges" on the social media platform. Speaking at the STAT Summit 2022, Ricks described the incident as "disappointing" and said that the apology which followed from Lilly did not "happen quickly enough". The drugmaker had issued an apology from its official Twitter account, @LillyPad, after an imposter Twitter account with the handle @EliLillyandCo tweeted that insulin would be free, amid political backlash and scrutiny into high medicine costs. Reporting by Bhanvi Satija in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.

☆ We're increasing price targets on 3 of our stocks, including 2 crushing the boarder market
▼ + stars: | 2022-11-08 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Following our price target changes on eight Club holdings last month, we're updating three more Tuesday to reflect their recent quarterly earnings reports and outlooks. It's also worth noting that we have not adjusted our Lilly price target since competitor Biogen (BIIB) reported positive topline results from a study to treat early Alzheimer's. Halliburton (HAL): Club price target increasing to $44 per share from $40 This update comes about two weeks after the oilfield services provider reported a stronger-than-expected third quarter . THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Eli Lilly says some staff want to leave Indiana because of abortion ban, Financial Times reports
▼ + stars: | 2022-11-06 | by ( ) www.reuters.com time to read: +1 min

Nov 6 (Reuters) - Some Eli Lilly and Co (LLY.N) employees have requested transfers from the drugmaker's Indiana operations after the U.S. state's lawmakers approved a bill that would ban most abortions there, the Financial Times reported on Sunday. Some staff had asked to relocate outside the state even though an Indiana judge has temporarily halted the ban, the Indiana-based pharmaceutical firm's chief executive David Ricks told the newspaper in an interview. His comments come after the Republican-controlled Indiana Senate passed a law in August banning most abortions. An Indiana judge blocked the state in September from enforcing the new law while Planned Parenthood and other healthcare providers challenge it in court. Eli Lilly did not provide details on how many staff have asked to move from Indiana, the FT said.

☆ Eli Lilly says some staff want to leave Indiana because of abortion ban - FT
▼ + stars: | 2022-11-06 | by ( ) www.reuters.com time to read: +1 min

Nov 6 (Reuters) - Some Eli Lilly and Co (LLY.N) employees have requested transfers from the drugmaker's Indiana operations after the U.S. state's lawmakers approved a bill that would ban most abortions there, the Financial Times reported on Sunday. Some staff had asked to relocate outside the state even though an Indiana judge has temporarily halted the ban, the Indiana-based pharmaceutical firm's chief executive David Ricks told the newspaper in an interview. An Indiana judge blocked the state in September from enforcing the new law while Planned Parenthood and other healthcare providers challenge it in court. Ricks said the new restrictions had created challenges for people to come to work in Indiana and that if Eli Lilly wanted to attract and retain the best staff, it had to grow in other locations, the FT said. Eli Lilly did not provide details on how many staff have asked to move from Indiana, the FT said.

Search resuls for: "Ricks"

25 mentions found